Neoadjuvant Osimertinib in EGFRm NSCLC
Phase II Trial of Neoadjuvant Osimertinib in Stage I-IIIA EGFR-Mutated NSCLC

Released: June 05, 2023

Activity

Progress
1
Course Completed